82 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected timing of clinical data, the re
8-K
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating
8-K
EX-99.1
4mih71rwlk
8 Jan 24
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
9:07am
8-K
41rj8
14 Dec 23
Other Events
7:04am
8-K
EX-99.1
xiqugn7t xjgk9336
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
8-K
kvpm gq02zqnumq83
29 Aug 23
Cost Associated with Exit or Disposal Activities
7:05am
8-K
a6ouuaav
22 Aug 23
Other Events
4:49pm
8-K
EX-99.1
k4v3gi
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
8-K
fysm4ag 6asi
24 Aug 22
Other Events
8:15am
8-K
EX-99.1
5ui v89blfs6u8
27 Jul 22
Entry into a Material Definitive Agreement
7:08am